These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 11403419)

  • 21. Inhibition of arterial thrombogenesis by quinapril but not losartan.
    Bavry AA; Li D; Zander DS; Phillips MI; Mehta JL
    J Cardiovasc Pharmacol Ther; 2000 Apr; 5(2):121-7. PubMed ID: 11150391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy.
    Watanabe K; Juan W; Narasimman G; Ma M; Inoue M; Saito Y; Wahed MI; Nakazawa M; Hasegawa G; Naito M; Tachikawa H; Tanabe N; Kodama M; Aizawa Y; Yamamoto T; Yamaguchi K; Takahashi T
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S93-7. PubMed ID: 12693379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined selective angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats.
    Richer C; Gervais M; Fornes P; Giudicelli JF
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):772-81. PubMed ID: 10598119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
    Brown NJ; Agirbasli M; Vaughan DE
    Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preservation of cardiac function and energy reserve by the angiotensin-converting enzyme inhibitor quinapril during postmyocardial infarction remodeling in the rat.
    Hügel S; Horn M; Remkes H; Dienesch C; Neubauer S
    J Cardiovasc Magn Reson; 2001; 3(3):215-25. PubMed ID: 11816618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
    Gonzalez W; Beslot F; Laboulandine I; Fournié-Zaluski MC; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1996 Aug; 278(2):573-81. PubMed ID: 8768706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats.
    Makino N; Hata T; Sugano M; Dixon IM; Yanaga T
    J Mol Cell Cardiol; 1996 Mar; 28(3):507-17. PubMed ID: 9011634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N(G)-nitro-L-arginine methyl ester-induced hypertension and natriuretic peptide gene expression: inhibition by angiotensin II type 1 receptor antagonism.
    Suo M; Kalliovalkama J; Pörsti I; Jolma P; Tolvanen JP; Vuolteenaho O; Ruskoaho H
    J Cardiovasc Pharmacol; 2002 Sep; 40(3):478-86. PubMed ID: 12198334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction.
    de Boer RA; Pinto YM; Suurmeijer AJ; Pokharel S; Scholtens E; Humler M; Saavedra JM; Boomsma F; van Gilst WH; van Veldhuisen DJ
    Cardiovasc Res; 2003 Feb; 57(2):434-42. PubMed ID: 12566116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats.
    Lantelme P; Lo M; Mullins JJ; Gharib C; Bizollon CA; Sassard J
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):476-81. PubMed ID: 8847862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.
    Muders F; Palkovits M; Bahner U; Kirst I; Elsner D; Jandeleit-Dahm K
    Pharmacol Res; 2001 Mar; 43(3):251-5. PubMed ID: 11401417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endogenous angiotensin II suppresses stretch-induced ANP secretion via AT1 receptor pathway.
    Oh YB; Gao S; Shah A; Kim JH; Park WH; Kim SH
    Peptides; 2011 Feb; 32(2):374-81. PubMed ID: 21056071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
    Shinohara H; Fukuda N; Soeki T; Sakabe K; Onose Y; Tamura Y
    Heart Vessels; 2002 Dec; 17(2):47-52. PubMed ID: 12541093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content.
    Smits JF; van Krimpen C; Schoemaker RG; Cleutjens JP; Daemen MJ
    J Cardiovasc Pharmacol; 1992; 20(5):772-8. PubMed ID: 1280740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy.
    Mukawa H; Toki Y; Shimauchi A; Matsui H; Morishima I; Okumura K; Ito T; Hayakawa T
    J Hypertens; 1997 Sep; 15(9):1027-32. PubMed ID: 9321751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension.
    Sakata K; Yoshida H; Obayashi K; Ishikawa J; Tamekiyo H; Nawada R; Doi O
    J Hypertens; 2002 Jan; 20(1):103-10. PubMed ID: 11791032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-converting enzyme inhibition by quinapril blocks the albuminuric effect of atrial natriuretic peptide in Type 1 diabetes and microalbuminuria.
    McKenna K; Smith D; Barrett P; Glenn A; Kesson CM; Connell J; Thompson CJ
    Diabet Med; 2000 Mar; 17(3):219-24. PubMed ID: 10784227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined inhibition of endothelin and angiotensin II receptors blocks volume load-induced cardiac hormone release.
    Leskinen H; Vuolteenaho O; Ruskoaho H
    Circ Res; 1997 Jan; 80(1):114-23. PubMed ID: 8978330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
    Goodfield NE; Newby DE; Ludlam CA; Flapan AD
    Circulation; 1999 Jun; 99(23):2983-5. PubMed ID: 10368114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.